Three Birds, One Excipient: Development of an Improved pH, Isotonic, and Buffered Ketamine Formulation for Subcutaneous Injection -- Wallach 2022
Optimal subcutaneous formulations of ketamine would have a pH and osmolality close to physiological levels without compromising on concentration or injection volume; the same strategy has potential to be readily adapted to other amine-based APIs.
Developing an on-body platform for effective post-operative pain management
In this article, Paolo Golfetto, Drug Delivery Systems Business Development Director at Stevanato Group, and Sheldon Moberg, Senior Vice-President of Drug Delivery at Bexson Biomedical, discuss an urgent requirement to meet an unmet patient need.